gray market semaglutide GLP-1 Drugs from the Could orforglipron reshape the GLP-1
Description
Roche for example paid $2.7bn to acquire privately held Carmot Therapeutics while AstraZeneca in-licensed an oral drug from Chinas Eccogene for $185m upfront (and $1.8bn of potential milestones)
Participants with obesity and knee osteoarthritis experienced average weight loss of 71.2 pounds alongside substantial relief from osteoarthritis pain
Some research points to ALAs potential for supporting insulin sensitivity
Switched to Ozari after 3 months of feeling completely unsupported
